WHI-P97

WHI-P97 is a potent and selective JAK-3 inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo[1].

Product Specifications

CAS Number

[211555-05-4]

UNSPSC

12352005

Hazard Statement

H315, H317, H319, H335

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/WHI-P97.html

Purity

99.70

Solubility

DMSO : 3.33 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

BrC1=CC(NC2=NC=NC3=CC(OC)=C(OC)C=C32)=CC(Br)=C1O

Molecular Formula

C16H13Br2N3O3

Molecular Weight

455.10

Precautions

H315, H317, H319, H335

References & Citations

[1]R Malaviya, et al. Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4- (3', 5'-dibromo-4'-hydroxyphenyl) amino-6,7-dimethoxyquinazoline (WHI-P97) . J Pharmacol Exp Ther. 2000 Dec;295 (3) :912-26.